Table S1. Treatment regimens in second-, third-, and fourth-line chemotherapy

|  |  |  |
| --- | --- | --- |
| Second-line treatment | Eligiblen = 114 | Ineligiblen = 142 |
| Taxan | 63 | 102 |
| Irinotecan (+platinum or other) | 45 | 23 |
| Other | 5 | 10 |
| nivolumab or pembrolizumab | 1 | 5 |
| Ramucirumab monotherapy | 0 | 2 |
| Adding ramucirumab | 22 | 37 |
| Adding trastuzumab | 5 | 6 |

Treatment discontinuation with PD (n=243) or AE (n=2)

|  |  |  |
| --- | --- | --- |
| Third-line treatment | Eligiblen = 83 | Ineligiblen = 74 |
| Taxan | 42 | 25 |
| Irinotecan (+platinum or other) | 20 | 19 |
| Nivolumab or pembrolizumab | 16 | 19 |
| FTD/TPI | 1 | 0 |
| Ramucirumab monotherapy | 1 | 0 |
| Trastuzumab deruxtecan | 1 | 2 |
| Other | 2 | 9 |
| Adding ramucirumab | 5 | 5 |

Treatment discontinuation with PD (n=147) or AE (n=2)

|  |  |  |
| --- | --- | --- |
| Fourth-line treatment | Eligiblen = 37 | Ineligiblen = 16 |
| Taxan | 14 | 3 |
| Irinotecan (+platinum or other) | 5 | 0 |
| Nivolumab or pembrolizumab | 4 | 4 |
| FTD/TPI | 6 | 8 |
| Ramucirumab monotherapy | 0 | 0 |
| Trastuzumab deruxtecan | 1 | 0 |
| Other | 7 | 1 |
| Adding ramucirumab | 1 | 2 |

PD, progressive disease; AE, adverse events; FTD/TPI, trifluridine/tipiracil.